Bedaquiline, Pretomanid, and Linezolid for Multidrug-Resistant Tuberculosis Treatment in the United States: A BIG Deal

Journal Article Corrected proof Bedaquiline, Pretomanid, and Linezolid for Multidrug-Resistant Tuberculosis Treatment in the United States: A BIG Deal Get access Carlos Acuña-Villaorduña, Carlos Acuña-Villaorduña Department of Medicine, Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USASection of Infectious Diseases, Tuberculosis Clinic, Boston Medical Center, Boston, Massachusetts, USA Correspondence: C. J. Acuña-Villaorduña, Lemuel Shattuck Hospital, 170 Morton St, Jamaica Plain, MA 02118 (Carlos.Acuna-Villaorduna@bmc.org). Search for other works by this author on: Oxford Academic PubMed Google Scholar Pranay Sinha Pranay Sinha Department of Medicine, Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USASection of Infectious Diseases, Tuberculosis Clinic, Boston Medical Center, Boston, Massachusetts, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Clinical Infectious Diseases, ciad314, https://doi.org/10.1093/cid/ciad314 Published: 30 May 2023 Article history Received: 16 May 2023 Editorial decision: 19 May 2023 Accepted: 25 May 2023 Published: 30 May 2023 Corrected and typeset: 11 August 2023